Form 4: KalVista CDO Sells Shares for Tax Obligations

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, sold 2,649 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, Inc., reported changes in his beneficial ownership of common stock.
• On August 17, 2025, 4,203 shares of common stock were acquired through the vesting and settlement of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs).
• On August 18, 2025, 2,649 shares of common stock were sold at a price of $13.187 per share.
• The sale was a 'sell to cover' transaction, executed solely to satisfy tax withholding obligations arising from the vesting of equity awards, and was not a discretionary sale.
• Following these transactions, Christopher Yea directly beneficially owns 129,493 shares of KalVista Pharmaceuticals, Inc. common stock.
• Remaining derivative holdings include 5,322 Restricted Stock Units (vesting 1/16th quarterly from August 17, 2022) and 2,431 Restricted Stock Units (vesting 1/12th quarterly from November 17, 2022).

Sentiment

Score: 5

Explanation: The filing reports a routine 'sell to cover' transaction by an insider to satisfy tax obligations related to equity award vesting, which is a neutral event and does not indicate a change in company fundamentals or insider sentiment.

Positives

• The acquisition of 4,203 shares of common stock by the Chief Development Officer through the vesting of equity awards indicates the continued realization of long-term incentive compensation.

Negatives

• No specific negative implications are identified as the reported sale was solely to cover tax withholding obligations, not a discretionary disposition of shares.

Risks

• Misinterpretation of the share sale as a discretionary disposition rather than a mandatory 'sell to cover' for tax obligations.

Future Outlook

N/A

Management Comments

• The sale of shares was solely to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs), and does not represent a discretionary transaction.

Industry Context

N/A

Related Party Transactions

• The reported transactions involve an officer of the company, Christopher Yea, and are related to his equity compensation.

Stakeholder Impact

• Shareholders: Provides transparency regarding insider stock ownership changes, specifically a non-discretionary sale for tax purposes.
• Employees: Relevant for employees with similar equity compensation plans (RSUs/PSUs) as it illustrates the process of vesting and tax handling.

Next Steps

• Ongoing vesting of remaining Restricted Stock Units according to their respective schedules.

Key Dates

Recommendation

The filing details a routine 'sell to cover' transaction by a company officer to satisfy tax obligations arising from the vesting of equity awards. This type of transaction is not indicative of a change in the company's fundamental outlook or the officer's confidence in the company, and therefore does not warrant a change in investment recommendation based solely on this filing.

Keywords

KalVista Pharmaceuticals, KALV, insider trading, Form 4, stock sale, equity compensation, RSU, PSU, Chief Development Officer, Christopher Yea